Wess J, Gdula D, Brann M R
National Institute of Neurological Disorders and Stroke, Laboratory of Molecular Biology, Bethesda, MD 20892.
EMBO J. 1991 Dec;10(12):3729-34. doi: 10.1002/j.1460-2075.1991.tb04941.x.
The hydrophobic core of all muscarinic receptors contains several conserved serine, threonine and tyrosine residues, most of which do not occur in any other G-protein coupled receptor. Since these amino acids can serve as potential hydrogen bond donors or acceptors, we have tested the hypothesis that they may be involved in the selective binding of muscarinic ligands. To eliminate the OH groups present in these residues, we have created nine single point mutations in the rat m3 muscarinic receptor by converting serine and threonine residues to alanine, and tyrosine residues to phenylalanine. The ligand binding and functional properties of these receptors were studied after transient expression in COS-7 cells. Six out of the nine mutant receptors (threonine and tyrosine mutations) showed strong reductions (approximately 10- to 40-fold lower than the wild-type receptor) in agonist binding affinities and reduced potencies in agonist-induced activation of phosphoinositide hydrolysis. Their antagonist binding properties, however, were similar to those of the wild-type m3 receptor. Despite their location on different transmembrane domains (III, V, VI and VII), all six mutations are positioned at a similar level (one to two helical turns away from the membrane surface) within the outer leaflet of the plasma membrane and may thus define the plain in which muscarinic agonists (but not antagonists) bind to their target receptor.
所有毒蕈碱型受体的疏水核心包含几个保守的丝氨酸、苏氨酸和酪氨酸残基,其中大多数在其他G蛋白偶联受体中并不存在。由于这些氨基酸可作为潜在的氢键供体或受体,我们检验了一个假说,即它们可能参与毒蕈碱型配体的选择性结合。为消除这些残基中存在的羟基,我们通过将丝氨酸和苏氨酸残基转换为丙氨酸,以及将酪氨酸残基转换为苯丙氨酸,在大鼠m3毒蕈碱型受体中产生了9个单点突变。在COS-7细胞中瞬时表达后,研究了这些受体的配体结合和功能特性。9个突变受体中的6个(苏氨酸和酪氨酸突变)显示激动剂结合亲和力大幅降低(比野生型受体低约10至40倍),且激动剂诱导的磷酸肌醇水解激活效力降低。然而,它们的拮抗剂结合特性与野生型m3受体相似。尽管这6个突变位于不同的跨膜结构域(III、V、VI和VII)上,但它们都位于质膜外小叶内的相似水平(距膜表面一到两个螺旋圈),因此可能确定了毒蕈碱型激动剂(而非拮抗剂)与其靶受体结合的平面。